Introduction: Pancreatic neuroendocrine tumors (pNET) are rare and display clinical heterogeneity.
Aim(s): We propose a clinical risk stratification tool for well differentiated, metastatic pNET.
Materials and methods: Retrospective study using clinical, pathological and laboratory variables for univariate analyses in a consecutive multicenter cohort (N=312) with pathologically confirmed, sporadic, well differentiated (grade 1 or 2), metastatic (Stage IV) pNET diagnosed between 1993 and 2010 with a minimum follow-up of 5 years. Data are presented as the mean with standard deviation (SD) and/or 95% confidence interval (CI). Overall survival was calculated using the Kaplan-Meier method with log-rank testing for potentially prognostic factors.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Henning Jann
To read results and conclusion, please login ...
Further abstracts you may be interested in